NL
DE
About
We study the pathobiology of leukemia and bleeding disorders. Epigenetic processes are examined to identify new targets for precision medicine. Small molecules targeting chromatin factors are being developed to cure the disease.
Research group leader
dr. Bert van der Reijden
Aims
- To identify therapeutic targets and develop small molecules to cure blood cancer and bleeding disorders.
Changes in gene expression play a dominant role in the development of many blood cell disorders. These changes are caused by inherited and acquired mutations in transcription factors and epigenetic modifiers. Blood cell disorders also arise through changes in expression of nonmutated genes that affect chromatin biology.
My group determines how transcription factors and epigenetic modifiers affect gene expression at the molecular level and which gene programs are relevant for disease pathogenesis. Insight into these processes provide new targets for therapy. Based on our findings, small molecules are being synthesized that specifically correct malfunctioning proteins to normalize affected blood cell development.
